DeepMed Research

Pelcitoclax

Generic Name: Pelcitoclax

Drug Type: Small Molecule

Chemical Formula: C_₅₇H_₆₆ClF_₄N_₆O_₁₁PS_₄

CAS Number: 1619923-36-2

Unique Ingredient Identifier: 317UBD60ML

Background: Pelcitoclax is under investigation in clinical trial NCT04210037 (Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/refractory Small Cell Lung Cancer).

Clinical Trials

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Phase 1

Recruiting

Conditions: Advanced Endometrial Carcinoma
Metastatic Endometrial Carcinoma
Metastatic Fallopian Tube Carcinoma
Metastatic Platinum-Resistant Ovarian Carcinoma
Metastatic Primary Peritoneal Carcinoma
Recurrent Endometrial Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Cobimetinib
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Pelcitoclax

First Posted Date: 2023-01-20

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT05691504

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 4 locations

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: NHL, Adult

Interventions: Drug: APG-1252
Drug: Chidamide

First Posted Date: 2022-01-11

Last Posted Date: 2024-01-23

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 51

Registration Number: NCT05186012

Locations: 🇨🇳
Henan Provincial Oncology Hospital, Zhengzhou, Henanan, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Shanghai Jiao Tong University school of medicine Ruijin Hospital, Shanghai, China

and more 1 locations

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Phase 1

Terminated

Conditions: Neuroendocrine Tumors

Interventions: Drug: Pelcitoclax

First Posted Date: 2021-05-19

Last Posted Date: 2025-04-17

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 2

Registration Number: NCT04893759

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Phase 1

Withdrawn

Conditions: Myelofibrosis

Interventions: Drug: APG-1252
Drug: Ruxolitinib

First Posted Date: 2020-04-21

Last Posted Date: 2022-07-12

Lead Sponsor: Ascentage Pharma Group Inc.

Registration Number: NCT04354727

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: APG-1252
Drug: Paclitaxel

First Posted Date: 2019-12-24

Last Posted Date: 2022-07-12

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 28

Registration Number: NCT04210037

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Phase 1

Recruiting

Conditions: EGFR Positive Non-small Cell Lung Cancer

Interventions: Drug: APG-1252
Drug: Osimertinib Mesylate Tablets

First Posted Date: 2019-06-28

Last Posted Date: 2024-05-29

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 80

Registration Number: NCT04001777

Locations: 🇨🇳
Henan Provincial people's Hospital, Zhengzhou, Henan, China
🇨🇳
First Hospital of Jilin University, Chang chun, Jilin, China
🇨🇳
Jilin Provincial Cancer Hospital, Changchun, Jilin, China

and more 1 locations

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Phase 1

Terminated

Conditions: Small Cell Lung Cancer and Other Solid Tumors

Interventions: Drug: APG-1252

First Posted Date: 2018-01-02

Last Posted Date: 2021-08-27

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 24

Registration Number: NCT03387332

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Phase 1

Completed

Conditions: Small Cell Lung Cancer
Solid Tumor

Interventions: Drug: APG-1252

First Posted Date: 2017-03-15

Last Posted Date: 2022-07-12

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 50

Registration Number: NCT03080311

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy